
VadilloLab
We are interested in the role of neutrophils in solid tumor progression and the mechanisms circulating tumor cells employ to achieve metastasis
The Laboratory of Migration and Metastasis is based in the Oncology Research Unit at the Oncology Hospital of the National Medical Center. IMSS. Mexico City.


Research
Which are the roles of neutrophils in cancer progression and metastasis?
We focus our research on how neutrophils contribute to colorectal cancer progression and metastasis. Our work consists of analyzing neutrophil phenotype and function in situ and in studying neutrophil: cancer cell: interactions in vitro.

Neutrophils and cancer
Neutrophils are the most frequent leukocytes in human peripheral blood. They are in charge of pathogen killing but also contribute to chronic inflammation in conditions such as obesity. In cancer, their role is just beginning to be discovered. We focus our research on the role of neutrophils in the progression and metastasis of colorectal cancer and other solid tumors. The Oncology Hospital is one of the biggest colorectal cancer concentration centers in Mexico. The combination of both biomedical research and expert clinicians makes possible high-quality research always looking to benefit the patients treated in our institution.

Circulating Tumor Cells
Over 90% of cancer patients succumb to complications related to metastasis. Our laboratory is focused on establishing methodologies to quantify circulating tumor cells or their clusters. These cells can travel through peripheral blood or the lymphatic circulation and can extravasate to generate a clinically detectable lesion. Quantifying these cells is important to generate more information relevant to clinical treatment decisions and can help in predicting a patient´s cancer recurrence. Studying their mechanisms of extravasation could help in generating molecular targets to at least retard metastatic colonization.

Most recent publications
These articles reflect a transition from performing basic science to more clinical scenarios.
During the current pandemic, we have also applied our knowledge, trying to contribute to understanding the physiopathology of COVID-19.

The invasive margin of early-stage human colon tumors is infiltrated with neutrophils of an antitumoral phenotype
Neutrophils infiltrate several types of cancer; however, whether their presence is associated with disease progression remains controversial. Here, we show that colon tumors overexpress neutrophil chemoattractants compared to healthy tissues, leading to their recruitment to the invasive margin and the central part of colon tumors. Of note, tumor-associated neutrophils expressing tumor necrosis factor α, which usually represents an antitumoral phenotype, were predominantly located in the invasive margin. Tumor-associated neutrophils from the invasive margin displayed an antitumoral phenotype with higher ICAM-1 and CD95 expression than neutrophils from healthy adjacent tissues. A higher neutrophil/lymphocyte ratio was found at later stages compared to the early phases of colon cancer. A neutrophil/lymphocyte ratio ≤3.5 predicted tumor samples had significantly more neutrophils at the invasive margin and the central part. Moreover, tumor-associated neutrophils at the invasive margin of early-stage tumors showed higher ICAM-1 and CD95 expression. Coculture of colon cancer cell lines with primary neutrophils induced ICAM-1 and CD95 expression, confirming our in situ findings. Thus, our data demonstrate that tumor-associated neutrophils with an antitumoral phenotype characterized by high ICAM-1 and CD95 expression infiltrate the invasive margin of early-stage colon tumors, suggesting that these cells can combat the disease at its early courses. The presence of tumor-associated neutrophils with antitumoral phenotype could help predict outcomes of patients with colon cancer.

The extravasation cascade revisited from a neutrophil perspective
April 2021
Neutrophil extravasation is a critical event during immune responses to infection or injury that ensures survival. However, given the destructive potential of neutrophil effector molecules such as proteases and reactive oxygen species, strict control of neutrophil recruitment is required to avoid tissue damage. Neutrophil extravasation is a multistep process of adhesive interactions between neutrophils and components of the venular wall, that is, endothelium, basement membrane and pericytes. A plethora of proteins have been identified as critical regulators of each step that provide for compensatory mechanisms thus ensuring that extravasation can happen even if one mechanism is defective. Here, we discuss recent discoveries of how extravasation is regulated with emphasis on neutrophil-specific mechanisms; and discuss potential implications for future research.

Cancer Biology, Epidemiology, and
Treatment in the 21st Century: Current
Status and Future Challenges From a
Biomedical Perspective
December 2021
Since the second half of the 20th century, our knowledge about the biology of cancer has made extraordinary progress. Today, we understand cancer at the genomic and epigenomic levels, and we have identified the cell that starts neoplastic transformation and characterized the mechanisms for the invasion of other tissues. This knowledge has allowed novel drugs to be designed that act on specific molecular targets, the immune system to be trained and manipulated to increase its efficiency, and ever more effective therapeutic strategies to be developed. Nevertheless, we are still far from winning the war against cancer, and thus biomedical research in oncology must continue to be a global priority. Likewise, there is a need to reduce unequal access to medical services and improve prevention programs, especially in countries with a low human development index.
Leukocyte movement during immune responses
May 2022
Inflammation at several degrees can be triggered by infectious agents but also by endogenous molecules
upon tissue damage. Most of the time, innate immune mechanisms control harmful agents; however, if these strategies succumb, the mounting of immune responses must take place to maintain homeostasis. First, an infected or damaged tissue recruits different leukocytes by producing pro-inflammatory mediators and chemokines. The first cells to be recruited to an injured tissue are the neutrophils which in humans represent the most abundant leukocyte in peripheral blood (PB). Later on, others such as monocytes and lymphocytes arrive at the injured tissue to exert function. Every blood cell lineage is endowed with specific mechanisms and molecules to achieve recruitment; however, some parallelisms among these leukocytes can also be made. Migration relies on chemokine receptors, adhesion molecules, and the cytoskeleton connected to the outside portion of the leukocyte by adaptor proteins in the cytoplasm. The cytoskeleton is a biopolymer network composed of actin, microtubules, and intermediate filaments. All these polymers work in conjunction to deform a leukocyte and any other cell to recognize and respond to a stimulus dynamically. During an immune response, leukocyte recruitment occurs; however, mechanisms such as mature leukocyte intravasation from the bone marrow (BM) to PB also occur. Antigen-presenting cells (APCs) perform intravasation from inflamed tissues to lymphatic circulation to arrive at the lymph nodes (LNs). Moreover, homing to the LN by lymphoid cells occurs, and inside these organs, all these cells follow chemokine gradients to interact with each other. Strikingly, even platelets can exert migration; their interaction with other leukocytes is essential for proper movement. Finally, when the harmful agent disappears, the damaged tissue produces antiinflammatory mediators to turn off the immune response. Even at this stage, leukocyte movement is modulated to shut down the immune response. This chapter will review how leukocytes during immune responses traffic to different tissues as well as the general mechanisms these cells employ during these processes. After reading this chapter, the reader should be able to understand: (1) the general mechanisms leukocytes employ to exert movement; (2) the different steps of the leukocyte extravasation cascade; (3) that leukocyte movement in primary and secondary lymphoid organs (SLOs) is fundamental for responding to harmful agents; and (4) the general mechanisms to inhibit leukocyte movement during the resolution of inflammation.

COVID-19

The Biology of SARS-CoV-2: Towards understanding and treating COVID-19
June 2020
During the last two decades, three different epidemics, caused by three different coronaviruses, have affected humankind. The most recent, known as COVID-19, has caused in only five months, more than 340,000 deaths worldwide. Knowing the biology of coronavirus is key, not just to face the current pandemic, but to prepare ourselves for future epidemics. With this in mind, this article is focused on the biology of coronaviruses emphasizing SARS-CoV-2, the agent that causes COVID-19. This is a comprehensive review article, which covers different topics, from the biology and taxonomy of viruses, to the molecular biology of SARS-CoV-2, its mechanisms of action, and the immune response this virus elicits. We have also addressed clinical aspects of COVID-19, its methods of detection, treatment, and vaccines.

ADAM17/MMP inhibition prevents neutrophilia and lung injury in a mouse model of COVID-19
June 2022
Severe coronavirus disease 2019 (COVID-19) is characterized by lung injury, cytokine storm, and increased neutrophil-to-lymphocyte ratio (NLR). Current therapies focus on reducing viral replication and inflammatory responses, but no specific treatment exists to prevent the development of severe COVID-19 in infected individuals. Angiotensin-converting enzyme-2 (ACE2) is the receptor for SARS-CoV-2, the virus causing COVID-19, but it is also critical for maintaining the correct functionality of lung epithelium and endothelium. Coronaviruses induce activation of a disintegrin and metalloprotease 17 (ADAM17) and shedding of ACE2 from the cell surface resulting in exacerbated inflammatory responses. Thus, we hypothesized that ADAM17 inhibition ameliorates COVID-19-related lung inflammation. We employed a preclinical mouse model using intratracheal instillation of a combination of polyinosinic:polycytidylic acid (poly(I:C)) and the receptor-binding domain of the SARS-CoV-2 spike protein (RBD-S) to mimic lung damage associated with COVID-19. Histologic analysis of inflamed mice confirmed the expected signs of lung injury including edema, fibrosis, vascular congestion, and leukocyte infiltration. Moreover, inflamed mice also showed an increased NLR as observed in critically ill COVID-19 patients. Administration of the ADAM17/MMP inhibitors apratastat and TMI-1 significantly improved lung histology and prevented leukocyte infiltration. Reduced leukocyte recruitment could be explained by reduced production of proinflammatory cytokines and lower levels of the endothelial adhesion molecules ICAM-1 and VCAM-1. Additionally, the NLR was significantly reduced by ADAM17/MMP inhibition. Thus, we propose inhibition of ADAM17/MMP as a novel promising treatment strategy in SARS-CoV-2-infected individuals to prevent the progression toward severe COVID-19.

A Shift Towards an Immature Myeloid Profile in Peripheral Blood of Critically Ill COVID-19 patients
April 2021
Background: SARS-CoV-2, the etiological agent causing COVID-19, has infected more than 27 million people with over 894000 deaths worldwide since its emergence in December 2019. Factors for severe diseases, such as diabetes, hypertension, and obesity have been identified however, the precise pathogenesis is poorly understood. To understand its pathophysiology and to develop effective therapeutic strategies, it is essential to define the prevailing immune cellular subsets.
Methods: We performed whole circulating immune cells scRNAseq from five critically ill COVID-19 patients, trajectory and gene ontology analysis.
Results: Immature myeloid populations, such as promyelocytes-myelocytes, metamyelocytes, band neutrophils, monocytoid precursors, and activated monocytes predominated. The trajectory with pseudotime analysis supported the finding of immature cell states. While the gene ontology showed myeloid cell activation in immune response, DNA and RNA processing, defense response to the virus, and response to type 1 interferon. Lymphoid lineage was scarce. Expression of genes such as C/EBPβ, IRF1and FOSL2 potentially suggests the induction of trained immunity.
Conclusions: Our results uncover transcriptomic profiles related to immature myeloid lineages and suggest the potential induction of trained immunity.

Increased expression of hypoxia-induced factor 1alpha mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients
December 2021
Background: COVID-19 counts 46 million people infected and killed more than 1.2 million. Hypoxaemia is one of the main clinical manifestations, especially in severe cases. HIF1α is a master transcription factor involved in the cellular response to oxygen levels. The immunopathogenesis of this severe form of COVID-19 is poorly understood.
Methods: We performed scRNAseq from leukocytes from five critically ill COVID-19 patients and characterized the expression of hypoxia-inducible factor1α and its transcriptionally regulated genes. Also performed metanalysis from the publicly available RNAseq data from COVID-19 bronchoalveolar cells.
Results: Critically-ill COVID-19 patients show a shift towards an immature myeloid profile in peripheral blood cells, including band neutrophils, immature monocytes, metamyelocytes, monocyte-macrophages, monocytoid precursors, and promyelocytes-myelocytes, together with mature monocytes and segmented neutrophils. May be the result of a physiological response known as emergency myelopoiesis. These cellular subsets and bronchoalveolar cells express HIF1α and their transcriptional targets related to inflammation (CXCL8, CXCR1, CXCR2, and CXCR4); virus sensing, (TLR2 and TLR4); and metabolism (SLC2A3, PFKFB3, PGK1, GAPDH and SOD2).
Conclusions: The up-regulation and participation of HIF1α in events such as inflammation, immunometabolism, and TLR make it a potential molecular marker for COVID-19 severity and, interestingly, could represent a potential target for molecular therapy. Key messages Critically ill COVID-19 patients show emergency myelopoiesis. HIF1α and its transcriptionally regulated genes are expressed in immature myeloid cells which could serve as molecular targets. HIF1α and its transcriptionally regulated genes is also expressed in lung cells from critically ill COVID-19 patients which may partially explain the hypoxia related events.
Upcoming Events
- The Neutrophil 2022 International Simposiumsáb 03 de dicCiudad de México
Laboratory of Migration and Metastasis. Oncology Research Unit

Reyna Oregon
Bachelors student

Juan Badillo
Bachelors student

Carmen Fuentes
Laboratory Technician

Eduardo Vadillo Ph.D
Asociate Researcher
Contact
UMAE. Hospital de Oncología. Centro Médico Nacional S.XXI. Av Cuauhtémoc No. 330 Colonia Doctores. CP: 06720 CDMX. México
